Rewiring urea cycle metabolism in cancer to support anabolism
暂无分享,去创建一个
Arkaitz Carracedo | P. Szlosarek | A. Carracedo | A. Erez | R. Keshet | Ayelet Erez | Rom Keshet | Peter Szlosarek
[1] David M. Wilson,et al. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures , 2018, Cell.
[2] P. Cheng,et al. Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models , 2018, Oncology reports.
[3] G. Abou-Alfa,et al. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies , 2018, Cancer Chemotherapy and Pharmacology.
[4] N. Danial,et al. Grasping for aspartate in tumour metabolism , 2018, Nature Cell Biology.
[5] K. Nathanson,et al. Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity. , 2018, Cell metabolism.
[6] F. Izzo,et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. V. Vander Heiden,et al. Aspartate is an endogenous metabolic limitation for tumour growth , 2018, Nature Cell Biology.
[8] D. di Bernardo,et al. Induction of Nitric-Oxide Metabolism in Enterocytes Alleviates Colitis and Inflammation-Associated Colon Cancer , 2018, Cell reports.
[9] M. Snuderl,et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumors , 2018, Nature Cell Biology.
[10] P. L. Ipata,et al. Metabolic interaction between urea cycle and citric acid cycle shunt: A guided approach , 2018, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.
[11] Le Yin,et al. Elevated mitochondrial SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived nitric oxide , 2018, Oncogene.
[12] N. Tang,et al. Optimizing combination of liver‐enriched transcription factors and nuclear receptors simultaneously favors ammonia and drug metabolism in liver cells , 2018, Experimental cell research.
[13] A. Cheng,et al. Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] A. Carracedo,et al. Oil for the cancer engine: The cross-talk between oncogenic signaling and polyamine metabolism , 2018, Science Advances.
[15] P. Kearns,et al. The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100 , 2017, International journal of cancer.
[16] L. Romer,et al. Hypoxia Triggers SENP1 (Sentrin-Specific Protease 1) Modulation of KLF15 (Kruppel-Like Factor 15) and Transcriptional Regulation of Arg2 (Arginase 2) in Pulmonary Endothelium , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[17] G. Abou-Alfa,et al. A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma , 2017, Cancer.
[18] Sarah Jeanfavre,et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass , 2017, Science.
[19] Y. Xiong,et al. CLOCK Acetylates ASS1 to Drive Circadian Rhythm of Ureagenesis. , 2017, Molecular cell.
[20] Gregory A. Wyant,et al. mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient , 2017, Cell.
[21] W. Hung,et al. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients , 2017, Scientific Reports.
[22] A. Deutsch,et al. Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization , 2017, Molecular Cancer Therapeutics.
[23] Daniel S. Hitchcock,et al. Critical role for arginase 2 in obesity-associated pancreatic cancer , 2017, Nature Communications.
[24] Edmund R. S. Kunji,et al. Expression and putative role of mitochondrial transport proteins in cancer. , 2017, Biochimica et biophysica acta. Bioenergetics.
[25] Wei He,et al. PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration , 2017, Oncotarget.
[26] E. Closs,et al. Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression , 2017, Front. Immunol..
[27] P. Cheng,et al. Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies , 2017, Oncotarget.
[28] Kristie L. Rose,et al. Critical role of SIK3 in mediating high salt and IL-17 synergy leading to breast cancer cell proliferation , 2017, PloS one.
[29] S. Venneti,et al. Glutaminolysis: A Hallmark of Cancer Metabolism. , 2017, Annual review of biomedical engineering.
[30] Steven J. M. Jones,et al. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.
[31] F. del Caño-Ochoa,et al. Structural Insight into the Core of CAD, the Multifunctional Protein Leading De Novo Pyrimidine Biosynthesis. , 2017, Structure.
[32] Chiara Secondini,et al. Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade , 2017, Oncoimmunology.
[33] C. Thompson,et al. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine , 2017, The EMBO journal.
[34] C. Tanikawa,et al. Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53 , 2017, Science Advances.
[35] Benjamin P. C. Chen,et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells , 2017, Nature.
[36] G. Cook,et al. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Xiaomin Ying,et al. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues , 2017, Scientific Reports.
[38] A. Vashisht,et al. Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes , 2017, Molecular and Cellular Biology.
[39] N. Tang,et al. The activity of the carbamoyl phosphate synthase 1 promoter in human liver‐derived cells is dependent on hepatocyte nuclear factor 3‐beta , 2017, Journal of cellular and molecular medicine.
[40] C. Skibola,et al. Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity. , 2017, ACS chemical biology.
[41] Jeffrey E. Lee,et al. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma , 2017, PloS one.
[42] G. Stephanopoulos,et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors , 2016, Nature Medicine.
[43] Jennifer B Dennison,et al. Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. , 2017, Journal of the National Cancer Institute.
[44] D. Hansel,et al. Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase. , 2017, The American journal of pathology.
[45] M. Lai,et al. Silencing of argininosuccinate lyase inhibits colorectal cancer formation. , 2017, Oncology reports.
[46] S. Beck,et al. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial , 2017, JAMA oncology.
[47] H. Shimizu,et al. Metabolic Adaptation to Nutritional Stress in Human Colorectal Cancer , 2016, Scientific Reports.
[48] A. De Grassi,et al. AGC1/2, the mitochondrial aspartate-glutamate carriers. , 2016, Biochimica et biophysica acta.
[49] M. V. Vander Heiden,et al. Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. , 2016, Cell metabolism.
[50] B. V. Van Tine,et al. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas , 2016, Cell Death and Disease.
[51] M. Mann,et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity , 2016, Cell.
[52] Jeffrey T. Chang,et al. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation , 2016, Oncotarget.
[53] A. Kawai,et al. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance , 2016, Oncotarget.
[54] D. Fukumura,et al. Arginine dependence of tumor cells: targeting a chink in cancer’s armor , 2016, Oncogene.
[55] Emanuel J. V. Gonçalves,et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition , 2016, Nature.
[56] P. Szlosarek,et al. Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1 , 2016, Cell reports.
[57] Ashok Palaniappan,et al. Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer Progression , 2016, PloS one.
[58] G. Shulman,et al. Argininosuccinate synthetase regulates hepatic AMPK linking protein catabolism and ureagenesis to hepatic lipid metabolism , 2016, Proceedings of the National Academy of Sciences.
[59] Shuang Liu,et al. PGC-1α Promotes Ureagenesis in Mouse Periportal Hepatocytes through SIRT3 and SIRT5 in Response to Glucagon , 2016, Scientific reports.
[60] D. A. Foster,et al. Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells* , 2016, The Journal of Biological Chemistry.
[61] Jie Yuan,et al. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer , 2015, Scientific Reports.
[62] M. Lai,et al. Argininosuccinate lyase is a potential therapeutic target in breast cancer. , 2015, Oncology reports.
[63] Senlin Ma,et al. Co-expression of the carbamoyl-phosphate synthase 1 gene and its long non-coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma , 2015, Molecular medicine reports.
[64] E. Ruppin,et al. Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis , 2015, Nature.
[65] A. Vazquez,et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis , 2015, Nature Cell Biology.
[66] M. V. Heiden,et al. Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.
[67] C. Dang,et al. MYC and metabolism on the path to cancer. , 2015, Seminars in cell & developmental biology.
[68] D. Sabatini,et al. An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.
[69] Y. Bhutia,et al. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. , 2015, Cancer research.
[70] Eyal Gottlieb,et al. Oncometabolites: tailoring our genes , 2015, The FEBS journal.
[71] M. Lai,et al. Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines , 2015, Scientific Reports.
[72] K. Kelly,et al. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors , 2015, Clinical Cancer Research.
[73] M. V. Vander Heiden,et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. , 2015, Cancer research.
[74] H. Erbaş,et al. Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. , 2014, Balkan medical journal.
[75] S. Fan,et al. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma , 2015, Investigational New Drugs.
[76] D. Nguyen,et al. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. , 2014, Anticancer research.
[77] L. Boon,et al. C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation , 2014, Oncogenesis.
[78] P. Mariottini,et al. Polyamines metabolism and breast cancer: state of the art and perspectives , 2014, Breast Cancer Research and Treatment.
[79] G. Cline,et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.
[80] Ting-feng Wu,et al. Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy , 2014, Tumor Biology.
[81] Yingming Zhao,et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. , 2014, Cell metabolism.
[82] A. Longo,et al. The Human Gene SLC25A29, of Solute Carrier Family 25, Encodes a Mitochondrial Transporter of Basic Amino Acids* , 2014, The Journal of Biological Chemistry.
[83] Yong-jie Lu,et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. , 2014, Cancer Research.
[84] Tijana Stankovic,et al. Identification of Novel Genetic Alterations in Samples of Malignant Glioma Patients , 2013, PloS one.
[85] P. Szlosarek,et al. Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges , 2013, Cancer research and treatment : official journal of Korean Cancer Association.
[86] N. Avliyakulov,et al. Proteomic Identification of Mitochondrial Targets of Arginase in Human Breast Cancer , 2013, PloS one.
[87] Ralph J DeBerardinis,et al. Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.
[88] M. Lai,et al. Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide , 2013, Molecular Cancer Therapeutics.
[89] M. Wangpaichitr,et al. Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction , 2013, Molecular Cancer Therapeutics.
[90] Guoyao Wu,et al. Nitric oxide and energy metabolism in mammals , 2013, BioFactors.
[91] C. Ludwig,et al. A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia , 2013, Cell reports.
[92] P. Szlosarek,et al. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells , 2013, Cancer & metabolism.
[93] S. Glynn,et al. The yin and yang of nitric oxide in cancer progression. , 2013, Carcinogenesis.
[94] A. Wilk,et al. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia , 2013, Leukemia.
[95] Z. Mao,et al. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma , 2013, Journal of gastroenterology and hepatology.
[96] Yigong Shi,et al. A proposed role for glutamine in cancer cell growth through acid resistance , 2013, Cell Research.
[97] Peilong Lu,et al. L-glutamine provides acid resistance for Escherichia coli through enzymatic release of ammonia , 2013, Cell Research.
[98] A. Erez. Argininosuccinic aciduria: from a monogenic to a complex disorder , 2013, Genetics in Medicine.
[99] T. Crook,et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma , 2013, Cell Death and Disease.
[100] J. Wolchok,et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma , 2013, Investigational New Drugs.
[101] A. Tsirigos,et al. Mitochondria “fuel” breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells , 2012, Cell cycle.
[102] D. Glass,et al. Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.
[103] Kyongmin Kim,et al. NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells , 2012, Oncogene.
[104] J. Gribben,et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis , 2012, Cell Death and Disease.
[105] Hui Yang,et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.
[106] Hui-Kuan Lin,et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.
[107] Jeffrey W Pollard,et al. KLF15 negatively regulates estrogen-induced epithelial cell proliferation by inhibition of DNA replication licensing , 2012, Proceedings of the National Academy of Sciences.
[108] S. Fan,et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma , 2012, Investigational New Drugs.
[109] G. Georgiou,et al. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. , 2012, Translational oncology.
[110] G. Georgiou,et al. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells , 2012, Anti-cancer drugs.
[111] Marshall Summar,et al. Requirement of argininosuccinate lyase for systemic nitric oxide production , 2011, Nature Medicine.
[112] P. Carmeliet,et al. Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.
[113] T. Wynn,et al. Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase , 2011, The Journal of Immunology.
[114] Abhishek K. Jha,et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011, Nature.
[115] Abhishek K. Jha,et al. Functional genomics reveals serine synthesis is essential in PHGDH-amplified breast cancer , 2011 .
[116] Shengyue Wang,et al. Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma , 2011, BMC Medical Genomics.
[117] D. Wheatley,et al. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis , 2011, Pigment cell & melanoma research.
[118] Brendan H. Lee,et al. Argininosuccinate lyase deficiency—Argininosuccinic aciduria and beyond , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.
[119] O. Stasyk,et al. Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells , 2011, Anti-cancer drugs.
[120] K. Robertson,et al. DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. , 2011, American Journal of Pathology.
[121] Damon H. May,et al. Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics. , 2011, Journal of proteome research.
[122] M. V. Vander Heiden. Targeting cancer metabolism: a therapeutic window opens. , 2011, Nature reviews. Drug discovery.
[123] A. Kavazis,et al. Nitric oxide and AMPK cooperatively regulate PGC‐1α in skeletal muscle cells , 2010, The Journal of physiology.
[124] I. Sheen,et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients , 2010, British Journal of Cancer.
[125] B. Delage,et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer , 2010, International journal of cancer.
[126] F. Izzo,et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] S. Curley,et al. Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. , 2010, ACS chemical biology.
[128] S. Hirohashi,et al. Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with Osteosarcoma , 2010, Molecular Cancer Therapeutics.
[129] R. Deberardinis,et al. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.
[130] Xiaokui K. Zhang,et al. Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. , 2009, American journal of clinical pathology.
[131] Paolo Sassone-Corsi,et al. Metabolism and cancer: the circadian clock connection , 2009, Nature Reviews Cancer.
[132] N. Savaraj,et al. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4 , 2009, Molecular Cancer Therapeutics.
[133] M. Beal. Faculty Opinions recommendation of S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. , 2009 .
[134] Takashi Nakagawa,et al. SIRT5 Deacetylates Carbamoyl Phosphate Synthetase 1 and Regulates the Urea Cycle , 2009, Cell.
[135] A. Godzik,et al. S-Nitrosylation of Drp1 Mediates β-Amyloid-Related Mitochondrial Fission and Neuronal Injury , 2009, Science.
[136] Akhilesh Pandey,et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. , 2008, Journal of proteome research.
[137] A. Alavi,et al. Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.
[138] Y. Leung,et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. , 2007, Cancer research.
[139] D. Fennell,et al. In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.
[140] F. Izzo,et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] S. Signoretti,et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.
[142] O. Levillain,et al. Localization and differential expression of arginase II in the kidney of male and female mice , 2005, Pflügers Archiv.
[143] F. Izzo,et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] Margaret King,et al. State of the art and perspectives , 2004, Machine Translation.
[145] M. Stuschke,et al. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation , 2003, International journal of cancer.
[146] N. Rioseco-Camacho,et al. Cloning and characterization of human ORNT2: a second mitochondrial ornithine transporter that can rescue a defective ORNT1 in patients with the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, a urea cycle disorder. , 2003, Molecular genetics and metabolism.
[147] A. Lavoinne,et al. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. , 2003, European journal of biochemistry.
[148] J. Ochoa,et al. Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine* , 2002, The Journal of Biological Chemistry.
[149] J. Ochoa,et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. , 2002, The Journal of biological chemistry.
[150] C. Cabella,et al. Agmatine modulates polyamine content in hepatocytes by inducing spermidine/spermine acetyltransferase. , 2001, European journal of biochemistry.
[151] S. Almashanu,et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter , 1999, Nature Genetics.
[152] S. Matsufuji,et al. Agmatine Suppresses Proliferation by Frameshift Induction of Antizyme and Attenuation of Cellular Polyamine Levels* , 1998, The Journal of Biological Chemistry.
[153] D. Reis,et al. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. , 1996, The Biochemical journal.
[154] S. Klahr,et al. Partial cloning and characterization of an arginine decarboxylase in the kidney. , 1995, Kidney international.
[155] J L Cleveland,et al. The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[156] K. Chen,et al. The evolutionary history of the first three enzymes in pyrimidine biosynthesis , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[157] C. Allegra,et al. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. , 1987, The Journal of biological chemistry.
[158] Holmes Fl,et al. Hans Krebs and the discovery of the ornithine cycle. , 1980 .
[159] F L Holmes,et al. Hans Krebs and the discovery of the ornithine cycle. , 1980, Federation proceedings.
[160] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.
[161] H. Krebs. The History of the Tricarboxylic Acid Cycle , 2015, Perspectives in biology and medicine.
[162] H. Krebs. The citric acid cycle: A reply to the criticisms of F. L. Breusch and of J. Thomas. , 1940, The Biochemical journal.